United Therapeutics (NASDAQ: UTHR)
You’re reading a free stock page from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
United Therapeutics Returns vs. S&P
|1 Year||5 Year||5 Year Annualized||Since IPO|
United Therapeutics Company Info
A biotechnology company focused on the development and commercialization of innovative therapeutic products for patients with chronic and life-threatening cardiovascular, cancer and infectious diseases.
News & Analysis
These 10 women CEOs are showing the value of leadership diversity.
Every one of the company's products booked a revenue gain in Q2.
Will future Tyvaso revenue growth push United Therapeutics to new heights?
Revenue and earnings fell from the prior-year period, but the drugmaker blew past analysts' estimates thanks to a combination of factors.
The stock has now fallen nearly 30% since the end of March.
The company moved to immediately monetize a promising drug candidate. For a cool $800 million up-front payment, investors can't complain.
A new collaboration is funneling tens of millions of dollars onto the diabetes company’s balance sheet.
Shares soar for the second day in a row. What can explain the bullish move?
UTHR earnings call for the period ending September 30, 2021.
UTHR earnings call for the period ending June 30, 2021.
UTHR earnings call for the period ending March 31, 2021.
UTHR earnings call for the period ending December 31, 2020.
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.